Activity of pazopanib in EWSR1-NFATC2 translocation-associated bone sarcoma

Pazopanib is a multi-kinase inhibitor that is currently approved for treatment of advanced renal cell carcinoma and chemotherapy-refractory soft tissue sarcoma. In this case report, we discuss the case of a patient with a EWSR1-NFATC2 fusion positive bone sarcoma who had exceptional tumor control th...

Descripción completa

Detalles Bibliográficos
Autores principales: Gouda, Mohamed A., Zarzour, Maria A., Vaporciyan, Ara A., Kairemo, Kalevi, Chuang, Hubert H., Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511123/
https://www.ncbi.nlm.nih.gov/pubmed/37736255
http://dx.doi.org/10.18632/oncoscience.587

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511123/
https://www.ncbi.nlm.nih.gov/pubmed/37736255
http://dx.doi.org/10.18632/oncoscience.587

Ejemplares similares